NCT04555837 2025-05-20Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell CancerM.D. Anderson Cancer CenterPhase 1/2 Completed24 enrolled 13 charts
NCT01848067 2025-05-04Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate CancerThomas Jefferson UniversityPhase 1/2 Completed9 enrolled 9 charts